Manufacturers can expect to face unforeseen hurdles when they begin to mass-produce a brand new pharmaceutical product, and in a pandemic, there are bound to be supply chain problems as well. But in late 2020, Pfizer was delivering fewer doses than the government expected and then-federal officials told NPR they did not know why.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy